The Impact of Sacrubitril/Nalsartan on Clinical Treatment and hs-cTnT and NT-ProBNP Serum Levels and the Left Ventricular Function in Patients with Chronic Heart Failure

Chronic heart failure (CHF) seriously affects the quality of patients' lives. Sacrubitril/valsartan is a combination angiotensin receptor-neprilysin inhibitor, a new therapeutic drugs to treat CHF. This study aims to observe the impact of sacrubitril/valsartan on clinical treatment and high-sensitivity cardiac troponin T (hs-cTnT), N-terminal pro-brain natriuretic peptide (NT-ProBNP) serum levels, the improvement of the left atrial diameter (LAD) and left ventricular end diastolic dimension (LVEDD), and the left ventricular ejection fraction (LVEF) in patients with CHF. 120 patients were randomly divided into a sacrubitil/valsartan group and a valsantan group, with 60 cases in each. Patients in the sacrubitil/valsartan group were administered sacrubitril/valsartan; while in the valsantan group, they were administered valsartan. The clinical effects, adverse reactions, and rehospitalization were observed eight weeks later, and hs-cTnT and NT-ProBNP serum levels and LAD, LVEDD, and LVEF were assayed. There were 53 cases of positive effect in the sacrubitil/valsartan group and 42 in the valsartan group (P < 0.05). Eight participants demonstrated adverse reactions in the sacrubitil/valsartan group, while 17 in the control group (P < 0.05). Hs-cTnT and NT-ProBNP serum levels, the measurements of LAD, LVEDD, and LVEF in the sacrubitil/valsartan group before the treatments were (24.47 +/- 7.54) pg/mL. (10.356.94 +/- 5,447.68) pg/mL, (49.41 +/- 5.22) mm, (68.06 +/- 6.20) mm and (31.12 +/- 6.65) %; in the valsartan group were (29.752 +/- 10.03) pg/ mL, (9,518.17 +/- 5,905.17) pg/mL, (49.65 +/- 4.91) mm. (67.06 +/- 3.97) mm, and (30.41 +/- 6.11) % (P > 0.05), while in the sacrubitil/valsartan group, the values decreased after the treatments to (17.92 +/- 4.74) pg/mL, (3,881.59 +/- 2,087.79) pg/mL. (42.18 +/- 4.87) mm, (60.35 +/- 7.12) mm and (45.35 +/- 4.49)%; in the valsartan group to (25.81 +/- 7.36) pg/mL, (6,278.35 +/- 2,643.11) pg/mL, (46.53 +/- 4.80) mm, (64.51 +/- 4.34) mm, and (36.47 +/- 5.21) % (P < 0.05). There were significant differences within the same group, before and after treatments (P < 0.05). Sacrubitril/valsartan treatment of patients with CHF improves their symptoms and is deserving of clinical application. This is also evident from significantly improved levels of scrum hs-cTnT and NT-ProBNP and the left ventricular function.